https://www.selleckchem.com/pr....oducts/gkt137831.htm
RESULTS Median NT-proBNP was 911 pg/ml (interquartile range 464 to 1,613 pg/ml) at screening. Screening NT-proBNP was strongly associated with the primary endpoint, total HF hospitalizations and cardiovascular death (rate ratio [RR] 1.68 per log increase in NT-proBNP, 95% confidence interval [CI] 1.53 to 1.85; p 57% (18%). Decreases in NT-proBNP predicted lower subsequent risk of the primary endpoint. CONCLUSIONS Baseline NT-proBNP predicted HF events but did not modify the sacubitril/valsartan treatment effect in patients with HFpEF.
Like
Comment
Share
